Exposure to multiple chemicals may cause significant alterations of tissue dose of the toxic moiety of one or more of the individual chemicals. The change in target tissue dose of a chemical present in simple mixtures can be predicted when the determinants of disposition of each chemical, and the mechanism of toxicokinetic interaction between chemicals are understood at a quantitative level. Determinants of disposition include physiological (e.g., breathing rates, cardiac output, tissue volumes, blood flow rates), biochemical (e.g., kinetic constants for metabolism and protein binding), and physicochemical factors (e.g., blood:air and tissue:blood partition coefficients). Mechanisms of toxicokinetic interactions refer to the manner in which coexposure alters these determinants of disposition as compared to exposure to the individual chemicals. Interactions between chemicals can be described quantitatively with physiologically based pharmacokinetic (PBPK) models, which integrate these mechanistic determinants and permit prediction of alterations in tissue dose for various exposure situations by computer simulation. PBPK modeling studies of binary chemical interactions conducted so far indicate that inhibitory rather than potentiating metabolic interactions are more likely to be observed during multiple chemical exposures. As PBPK models of representative binary, tertiary and quaternary mixtures are developed, it will become increasingly possible to draw reliable conclusions about the risk associated with human exposure to chemical mixtures. -Environ Health Perspect 102(Suppl 9): 151-155 (1994) 
Introduction
Multichemical exposure is the rule rather than the exception in both the general and occupational environments. Simultaneous or sequential exposure to multiple chemicals may 
Physiologically Based Pharmacokinetic Modeling
Physiologically based pharmacokinetic (PBPK) modeling is the process of developing mathematical descriptions of the uptake and disposition of chemicals in which the interrelationships among the critical biological determinants are described as realistically as possible. In the PBPK modeling approach, the body is divided into a number of tissue compartments (Figure 1) (4) . The principal application of this biologically and mechanistically based approach is in the prediction of target tissue dose of the toxic parent chemical or its reactive metabolite. Using the tissue dose of the toxic moiety of a chemical in risk assessment provides a better basis of relating to the observed toxic effects than the external exposure concentration (5) . Because PBPK models facilitate the prediction of target tissue dose in people, they can help reduce the uncertainty associated with the conventional extrapolation procedures (6 (7) (8) (9) (10) due to changes in solubility and stability (11, 12) . Similarly, various dithiocarbamates form lipophilic complexes with inorganic lead, enhancing lead uptake across the blood-brain barrier, thus causing a greater accumulation in the lipid-rich brain compartments (13 Figure 3 . Model simulations of the area under the blood 2,5-hexanedione concentration vs time curve for 6-and 12-hr inhalation exposures of up to 10,000 ppm n-hexane. The solid lines were generated with a PBPK model assuming competitive interactions among nhexane, 2,5-hexanedione and methyl n-butyl ketone.
with experimental data on both chemicals obtained during coexposures, to test the validity of the hypotheses. Using the PBPK modeling approach, Andersen and Clewell (19) described the toxicokinetic interaction among n-hexane and its metabolites.
n-Hexane is metabolized by a saturable pathway yielding methyl n-butyl ketone (MnBK). MnBK is further metabolized by c0-1 oxidation to 2,5-hexanedione, the neurotoxic metabolite, and by a-oxidation and decarboxylation to pentanoic acid. Following a 6-hr exposure of F-344 rats to 500, 1000, 3000, and 10,000 ppm of n-hexane, the blood concentrations of n-hexane and MnBK increased linearly with increasing exposure concentrations, but 2,5-hexanedione (HD) showed anamolous behavior (20) . The concentration of HD at the end of hexane exposure increased substantially from 500 to 1000 ppm, then remained fairly constant between 1000 and 3000 ppm but was lower for the 10000 ppm n-hexane exposure than for the lower exposure levels. At high hexane exposure concentrations, the blood level of HD immediately following hexane exposure was lower than the eventual peak, indicating that inhibition of HD (Figure 4) . Inhibitory metabolic interactions between trichloroethylene and dichloroethylene, benzene and toluene, and m-xylene and toluene have also been described with a physiological modeling approach (21) (22) (23) . In these studies, the metabolic rate constants for each chemical were first determined by conducting gas uptake studies with individual chemicals, and then the metabolic inhibition constants were determined by conducting another series of gas uptake studies with both chemicals. The binary chemical gas uptake data indicating altered uptake of both chemicals during coexposures were analyzed with a PBPK model to test various hypotheses of inhibitory interaction (e.g., competitive, noncompetitive, uncompetitive). These studies considered the metabolic rate constants to be time-invariant. There are instances where such a description may not be sufficient, especially where inactivation of metabolizing enzymes occurs during the exposure.
Andersen et al. (24) found that the decline in the gas uptake chamber concentration of both cis-and trans-1,2-dichloroethylene could not be described with timeinvariant metabolic constants ( Figure 5 ). This indicated that the maximum rate of metabolism was decreasing during exposure to these compounds. The gas uptake data was successfully described by a PBPK model in which the rate of enzyme inactivation was proportional to a second order rate constant (Kd) times the square of the instantaneous rate of metabolism ( Figure  6 ). The square dependence on instantaneous metabolic rate indicated an interaction between a reactive metabolite and the enzyme-substrate complex in the rate limiting step for enzyme inactivation (25, 26 
